Partial Reconstitution of Photoreceptor cGMP Phosphodiesterase Characteristics in cGMP Phosphodiesterase-5*

Received for publication, January 23, 2001, and in revised form, March 15, 2001
Published, JBC Papers in Press, April 2, 2001, DOI 10.1074/jbc.M100626200

Alexey E. Granovsky‡ and Nikolai O. Artemyev§

From the Department of Physiology and Biophysics, University of Iowa College of Medicine, Iowa City, Iowa 52242

Photoreceptor cGMP phosphodiesterases (PDE6) are uniquely qualified to serve as effector enzymes in the vertebrate visual transduction cascade. In the dark-adapted photoreceptors, the activity of PDE6 is blocked via tight association with the inhibitory γ-subunits (Pγ). The Pγ block is removed in the light-activated PDE6 by the visual G protein, transducin. Transducin-activated PDE6 exhibits an exceptionally high catalytic rate of cGMP hydrolysis ensuring high signal amplification. To identify the structural determinants for the inhibitory interaction with Pγ and the remarkable cGMP hydrolytic ability, we sought to reproduce the PDE6 characteristics by mutagenesis of PDE5, a related cyclic GMP-specific, cGMP-binding PDE. PDE5 is insensitive to Pγ and has a more than 100-fold lower kcat for cGMP hydrolysis. Our mutational analysis of chimeric PDE5/PDE6α enzymes revealed that the inhibitory interaction of cone PDE6 catalytic subunits (PDE6α) with Pγ is mediated primarily by three hydrophobic residues at the entry to the catalytic pocket, Met758, Phe777, and Phe781. The maximal catalytic rate of PDE5 was enhanced by at least 10-fold with substitutions of PDE6α-specific glycine residues for the corresponding PDE5 alanine residues, Ala606 and Ala612. The Gly residues are adjacent to the highly conserved metal binding motif His-Asn-X-X-His, which is essential for cGMP hydrolysis. Our results suggest that the unique Gly residues allow the PDE6 metal binding site to adopt a more favorable conformation for cGMP hydrolysis.

cGMP phosphodiesterases (PDE6) play the role of effector enzymes in the vertebrate visual transduction cascade. In retinal rod cells, photoexcited rhodopsin induces GDP/GTP exchange on the visual G protein, transducin (Gt), and liberated GtGTP activates PDE6. A homologous cascade operates in cone photoreceptors. cGMP hydrolysis by active PDE6 results in the closure of cGMP-gated channels in the plasma membrane (1, 2). The key attributes of the visual cascade, low noise and high gain signal amplification, place specific requirements on PDE6. The enzyme must have a very low basal cGMP hydrolytic rate in the dark-adapted photoreceptors and a very high catalytic rate in the transducin-activated state. This is achieved through two unique features of PDE6: the inhibitory interaction of the catalytic subunits with the γ-subunit and an exceptionally high kcat value for cGMP hydrolysis when the inhibition is turned off.

The lack of a practical expression system for PDE6 (3–5) has stalled the progress in determining the structural basis of PDE6 function. We have begun to study the structure and function relationship of PDE6 by constructing chimeras between cone PDE6α and cGMP binding cGMP-specific PDE (PDE5 family) (5, 6). PDE5 and PDE6 display a high degree of identity (45–48%) between the catalytic domains, a strong substrate selectivity for cGMP, and similar sensitivity to a common set of competitive inhibitors (7–9). Yet, the reported maximal rate of cGMP hydrolysis by PDE5 catalytic dimers is only ~10 moles of cGMP per mole of PDE5sec, which is ~400–550-fold lower than the kcat estimates for PDE6 (5, 10–15). Furthermore, the activity of PDE5 is unaffected by the PDE6 γ-subunit (5, 6). This, and a robust functional expression of PDE5 using the baculovirus/insect cell system (16), makes PDE5 a valuable tool for “gain of PDE6 function” experiments. Recently, we have shown that a substitution of the segment PDE5-(773–820) by the corresponding PDE6α-(737–784) sequence in the wild-type PDE5 or in a PDE5/PDE6α chimera containing the catalytic domain of PDE5 results in chimeric enzymes capable of inhibitory interaction with Pγ. (6). Alanine-scanning mutational analysis of the previously identified Pγ cross-linking site, PDE6α-(750–760) (17), revealed a critical Pγ-interacting residue, Met758 (6). A model of the PDE6α catalytic domain, Met758 faces the opening of the catalytic cavity (6). We then hypothesized that Pγ may interact with additional nonconserved residues located at the perimeter of the cavity, thus allowing Pγ to serve as a lid on the catalytic pocket. In this study, we mutated three candidate Pγ contact residues identified from the model of PDE6α and examined these mutants for inhibition by Pγ.

The rationale for our search of the catalytic determinants of PDE6 was based on biochemical evidence and the crystal structure of the PDE4 catalytic domain (18–20), which suggests the critical role of the two highly conserved metal binding motifs, His-Asn-X-X-His (I) and His-Asp-X-X-His (II), in the hydrolysis of cyclic nucleotides. We replaced PDE6α domains containing motifs I and II into PDE5. Resulting chimeric PDEs and corresponding mutants have been analyzed to test our hypothesis.

EXPERIMENTAL PROCEDURES

Materials—cGMP was obtained from Roche Molecular Biochemicals. [3H]cGMP was a product of Amersham Pharmacia Biotech. All restriction enzymes were purchased from New England Biolabs. AmpliTaq® DNA polymerase was a product of PerkinElmer Life Sciences, and Pfu DNA polymerase was a product of Stratagene. Rabbit polyclonal His-

* This work was supported by National Institutes of Health (NIH) Grant EY-10845. The services provided by the Diabetes and Endocrinology Research Center of the University of Iowa were supported by NIH Grant DK-25295. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ Recipient of the American Heart Association Heartland Affiliate Predoctoral Fellowship.

§ Established Investigator of the American Heart Association. To whom correspondence should be addressed. Tel.: 319-335-7864; Fax: 319-335-7330; E-mail: nikolai-artemyev@uiowa.edu.

1 The abbreviations used are: PDE, cGMP phosphodiesterase; Pγ, γ-subunit of PDE6; PDE6α, α’-subunit of cone PDE6; PDE5, cGMP binding, cGMP-specific PDE (PDE5 family); PCR, polymerase chain reaction; HPLC, high performance liquid chromatography.
probe (H-15) antibodies were purchased from Santa Cruz Biotechnology. Zaprofin and all other reagents were purchased from Sigma. 

Cloning of PDE5- and PDE6 Mutants—PDE5 mutants were generated based on the pET11a-Py expression vector (21, 22). Residues Ile608 and Ile87 were substituted for alanine using PCR-directed mutagenesis. PCR products were obtained using a forward primer containing a Ndel site and a reverse primer containing the mutations and a BamHI site. The fragments were digested with Ndel/BamHI and subcloned into the pET11a-Py digested with the same enzymes.

Preparation of PDE5- and PDE6 Mutants—The Pysubunit and its mutants were expressed in Escherichia coli and purified on a SP-Sepharose fast flow column and on a C₄ HPLC column (Microsorb-MW, Rainin) as described (22). Purified proteins were lyophilized, dissolved in 20 mM Tris-HCl buffer, pH 7.8, and resuspended in 1 mM Tris-HCl buffer, pH 7.8 containing 50 mM NaCl, and stored at −80 °C until use.

Cloning of Chi20 and Chi21—The constructs for expression of PDE5/ PDE6a’ chimeras were obtained based on pFastBacHTb-PDE5 vector (5). To obtain Chi20 and Chi21, original restriction sites in pFastBacHTb-PDE5, SpeI and SpI1, were eliminated and re-introduced at desired positions to allow a site-directed cloning of PDE6a’ fragments into PDE5. To eliminate two SpeI restriction sites located within the 3’-untranslated region of PDE5 cDNA and the unique SpHI site from the multiple cloning sequence of the vector, pFastBacHTb-PDE5 was digested with SpeI/SpHI and treated with mung bean nuclease. New SpeI and SpHI restriction sites (PDE5 codons for ArgGxx-His-Glu-AlaGxx and AlaGxx-LeuGxx-LysGxx, respectively) were introduced into the vector using a QuikChange™ kit (Stratagen). To obtain Chi21 (Fig. 1), a synthetic oligonucleotide duplex, encoding for PDE6a’-(561–574), was ligated into the modified pFastBacHTb-PDE5 vector digested with SpeI and SpHI. To generate Chi20, a PCR fragment, encoding for PDE6a’-(575–617), was digested with SpeI/SpHI and ligationed into the modified pFastBacHTb-PDE5 vector digested with Spel/BspI(partial). The resulting construct was digested with SpeI/SpHI and ligated to the synthetic oligonucleotide duplex encoding for PDE6a’-(561–574).

Site-directed Mutagenesis of PDE5 and Chi16—Site-directed mutagenesis of PDE5 was performed using a QuikChange™ kit. A pair of complementary oligonucleotides encoding for the Ala608–Gly and Ala612–Gly substitutions (PDE5A608G/A612G) was used to PCR-amplify the pFastBacHTb-PDE5 vector. The PCR product was treated with DpnI to eliminate the template and was transformed into E. coli DH5α. Chi16 mutants with single substitutions of residues Lys694, Phe777, and Phe791 by Ala were constructed using PCR-directed mutagenesis. A unique Nhel site (PDE5 codons for ProGxx-LeuGxx) was introduced into Chi16 using a QuikChange™ kit. The 5’-primer sequence included the Nhel recognition site. Reverse primers contained a desired mutation and the StuI site. The PCR products were digested with Nhel/StuI and subcloned into the modified Chi16 vector cut with the same enzymes. Sequences of all mutants were verified by automated DNA sequencing at the University of Iowa DNA Core Facility.

Expression and Purification of Recombinant PDEs and their Mutants—Sf9 cells were harvested at 60 h after infection, washed with 20 mM Tris-HCl buffer, pH 7.8 containing 50 mM NaCl, and resuspended in the same buffer containing a protease inhibitor mixture (10 µg/ml pepstatin, 5 µg/ml leupeptin, and 0.2 mM phenylmethylsulfonyl fluoride). The cell suspensions were sonicated using 30-s pulses for a total duration of 3 min. The supernatants (100,000 × g, 45 min) were loaded onto a column with a His-Bind resin (Novagen) equilibrated with 20 mM Tris-HCl buffer, pH 7.8, containing 10 mM imidazole. The resin was washed with a 5 × volume of the buffer containing 500 mM NaCl and 25 mM imidazole. Proteins were eluted with the buffer containing 250 mM imidazole. β-mercaptoethanol (2 mM) was added to the eluate. PDE5, Chi20, Chi21, and PDE5A608G/A612G were additionally purified using ion-exchange chromatography on a Mono Q® HR 5/5 column (Amersham Pharmacia Biotech). Purified proteins were dialyzed against 1/10 glyceral and stored at −20 °C.

Other Methods—PDE activity was measured using [3H]cGMP as described (23, 24). Less than 15% of cGMP was hydrolyzed during these reactions. The Kᵢ values for inhibition of PDE activity by Py and zaprinast were measured using 0.5 µM cGMP (i.e. <35% of the Kᵥ value) for chimeric and mutant PDEs. Protein concentrations were determined by the method of Bradford (25) using IgG as a standard or by using calculated extinction coefficients at 280 nm. The molar concentrations of Chi20, Chi21, and mutant PDEs, [PDE], were calculated based on the fraction of PDE protein in preparations, and the molecular mass of 93.0 kDa. The fractional concentrations of PDE were determined from analysis of the Coomassie Blue-stained SDS gels using a HP ScanJet II CX7 scanner and Scion Image Beta 4.02 software. A typical fraction of Chi16 mutants in partially purified preparations was 10–15%. A typical fraction of purified Chi20, Chi21, and PDE5A608G/A612G was 65–70%. The Kᵥ values for cGMP hydrolysis were calculated as Vᵥ/µₜ[PDE]. SDS-polyacrylamide gel electrophoresis was performed by the method of Laemmli (26) in 10–12% acrylamide gels. For Western immunoblotting, proteins were transferred to nitrocellulose (0.1 µm, Schleicher & Schuell) and analyzed using rabbit His-probe (H-15) or sheep anti-PDE6a’ antibodies (5, 6, 27). The antibody-antigen complexes were detected using anti-rabbit or anti-goat/sheep IgG conjugated to peroxidase and ECL reagent (Amersham Pharmacia Biotech.). Fitting the experimental data to equations was performed with nonlinear least squares criteria using GraphPad Prizm Software. The Kᵥ, Kᵥm, and ICᵥ₅₀ values are expressed as mean ± S.E. for three independent measurements.

RESULTS

Mutational Analysis of the Py Binding Site of PDE6a’—Previously, we demonstrated that PDE5/PDE6a’ chimeras containing a PDE6a’ sequence, PDE6a’-(737–784), are effectively inhibited by Py, and two residues, Met758 and Gin762, participate in the inhibitory interaction (6). Based on the model structure of PDE6a’ (6), three solvent-exposed nonconserved PDE6a’ residues, Lys739, Phe777, and Phe791, were chosen for further mutational analysis of the Py binding region (Fig. 1A). A PDE5/PDE6a’ chimera Chi16 (6), served as a template for single substitutions of these residues by Ala. The Chi16 mutants were expressed in Sf9 insect cells and partially purified. Expression of the K769A, F777A, and F781A mutants have yielded similar amounts of soluble protein (50–100 µg/100 ml of culture). Neither of these mutations significantly affected the catalytic properties of chimeric PDE. The Kᵥ and Kᵥm values for cGMP hydrolysis for all three mutants were in the 3–10 µM range, and the 5–10 s⁻¹ range, respectively (Table I).
As an additional control for the structural integrity of the catalytic site, mutants of Chi16 were tested for the PDE activity inhibition by zaprinast, a specific competitive inhibitor of PDE5 and PDE6. The largest change, a 2-fold increase in the IC₅₀ value, was caused by the F781A substitution (Table I). Nonetheless, such a change represents an insignificant loss of affinity to zaprinast.

The test of the ability of Chi16 mutants to be inhibited by Py showed that the K769A mutation had no effect on the inhibitory interaction with Py (Kᵢ 2.9 µM) (Table I). Two other mutants, F777A and F781A, displayed significant impairments in the inhibition by Py. The F777A substitution reduced both the maximal inhibition of PDE activity by Py (−45%) and the Kᵢ value (Kᵢ 19 nm). The inhibition of F781A mutant by Py also was incomplete (−65%) and associated with an increase in the Kᵢ value (Kᵢ 31 nm) (Fig. 2A and Table I).

**Effects of the C-terminal Py Mutants on the Catalytic Activity of Mutant Chi16—C-terminal Py mutants were designed based on the evidence for the critical role of the Py C terminus in PDE6 inhibition (21, 28). The two extreme C-terminal Py residues, Ile66 and Ile87, were replaced by Ala to obtain the PDE6a and PyI87A mutants, respectively. The Py mutants were analyzed for their ability to inhibit trypsin-activated PDE6a (tPDE), Chi16, and the M758A, F777A, and F781A mutants (Fig. 2; Table I). PyI86A and PyI87A fully inhibited tPDE activity. However, the potency of the inhibition was reduced −4–5-fold (Kᵢ 0.75 nm for PyI86A and Kᵢ 0.65 nm for PyI87A, compared with Kᵢ 0.15–0.2 nm for Py). A similar increase in the Kᵢ values was observed from the inhibition of Chi16 activity by PyI86A (Kᵢ 13 nm) and PyI87A (Kᵢ 7 nm) (Fig. 2, B and C; Table I). Yet, PyI86A and PyI87A did not fully inhibit Chi16, maximal inhibition was 65 and 70%, respectively. (Fig. 2, B and C; Table I). No appreciable inhibition of M758A by either Py mutant was seen even at inhibitor concentrations as high as 5 µM. The inhibition of F777A by PyI86A was partial (45%) with the Kᵢ value of 96 nm, whereas PyI87A inhibited this Chi16 mutant with an even smaller maximal effect (25%, Kᵢ 64 nm). The F781A mutant was inhibited by PyI86A and PyI87A with Kᵢ values of 49 and 32 nm and maximal effects of 40 and 55%, respectively (Fig. 2, B and C; Table I).

**Catalytic Properties of PDE5/PDE6a’ Chimeras Containing the PDE6a’ Metal Binding Sites—Two conserved metal binding motifs found in all PDEs are absolutely critical for cyclic nucleotide hydrolytic activity (18–20). To identify the structural elements responsible for the unique catalytic properties of PDE6, chimeric PDE5/PDE6a’ have been generated by introduction into PDE5 of PDE6a’ domains containing metal binding motifs, I and II. A replacement of the PDE6a’-(562–617) segment into PDE5 yields a chimeric PDE5/PDE6a’, Chi20, that incorporates both PDE6a’ metal binding sites and the connecting sequence (Fig. 1A). Chi20 was expressed in Sf9 cells as a functional enzyme at ~400 µg/100 ml and purified to ~65–70% purity (Fig. 1B). The catalytic characteristics of Chi20 were examined in comparison to those of PDE5 and native PDE6a’. PDE6a’ has reported Kᵢ (17–25 µM) and kₐcat (3500–4500 moles of cGMP per mole of PDE) values for cGMP hydrolysis that are ~5 and ~40-fold higher than the respective constants for PDE5 (5, 10–11, 14). The catalytic parameters of Chi20 were significantly different from those of PDE5. Chi20 hydrolyzed cGMP with the Kᵢ value of 12 µM, which is ~4-fold higher than the Kᵢ value for PDE5 but similar to that of PDE6a’ (Table I). The maximal activity of 116 moles of cGMP per mole of PDEs for Chi20 is ~10-fold higher than that of PDE5. Chi20 was inhibited by zaprinast with the IC₅₀ value of 0.35 µM, which is comparable with that of PDE5 (Table I).

To determine the role of individual metal binding motifs and their adjacent regions in cGMP hydrolysis by PDE6, we inserted a PDE6a’ fragment corresponding to the helix-α6 (20), PDE6a’-(562–574), into PDE5 (Chi21) (Fig. 1). The catalytic properties of Chi21 and the inhibition by zaprinast (Kᵢ 17 µM, Kₐcat of 110 moles of cGMP per mole of PDEs, and IC₅₀ 0.39 µM) were similar to those of Chi20.

**Catalytic Properties of the PDE5A608G/A612G Mutant—** The alignment of sequences from different PDE families corresponding to the α6 helix shows a glycine residue, PDE6a’ Gly656, conserved only in photoreceptor PDEs (Fig. 3A). A second Gly residue, PDE6a’ Gly566, is conserved in PDE6a’ and PDE6a, but substituted by Ala in PDE6β and PDE5 (Fig. 3A). To test the hypothesis that Gly656 and Gly566 of PDE6a’ are responsible for the differences in catalytic properties of Chi21 and PDE5, a doubly substituted mutant of PDE5, A608G and A612G, was expressed and purified from Sf9 cells. Similar to Chi20 and Chi21, PDE5A608G/A612G hydrolyzed cGMP with a Kᵢ value of 14 µM and a kₐcat value of 105 moles of cGMP per mole of PDEs (Table I).

**DISCUSSION**

An interaction between PDE6 catalytic and inhibitory Py subunits keeps the visual effector enzyme inhibited in the dark. Previous biochemical studies have established that the γ-subunit of photoreceptor PDE inhibits the enzyme activity by blocking its catalytic site (29). The major inhibitory domain has been localized to the Py C terminus (21, 28). Recently, we have demonstrated that Py inhibits the activity of PDE5/PDE6a’ chimera, Chi 16, containing residues PDE6a’-(737–784) (6).
FIG. 2. Effect of Pγ and C-terminal Pγ mutants on the catalytic activity of tPDE6α Chi16 and Chi16 mutants. A, inhibition of Chi16, F777A, and F781A PDE activity by Pγ. The activities of Chi16 (○), F777A (▲), and F781A (▼) (50–100 pm) were determined upon addition of increasing concentrations of Pγ. Reactions were initiated by addition of 0.5 μM of cGMP. The Kᵢ values (nM) calculated from the inhibition curves were 3.6 ± 0.4 (○), 19 ± 2 (▲), and 31 ± 5 (▼). B, inhibition of tPDE6α (□) (0.5 pm), Chi16 (○), F777A (▲), and F781A (▼) by PγI86A. The Kᵢ values (nM) calculated from the inhibition curves were 0.75 ± 0.08 (□), 13 ± 1 (○), 96 ± 13 (▲), and 49 ± 8 (▼). C, inhibition of tPDE6α (□), Chi16 (○), F777A (▲), and F781A (▼) by PγI87A. The Kᵢ values (nM) calculated from the inhibition curves were 0.65 ± 0.04 (□), 6.6 ± 1.0 (○), 64 ± 8 (▲), and 32 ± 2 nM (▼).

FIG. 3. The Pγ C terminus docked to the PDE6α catalytic site. A, an alignment (31) of PDE1–6 sequences corresponding to the helix-α6 (20). B and C, a model of the PDE6α was generated with SWISS-MODEL (32) using the coordinates of the PDE4 structure as a template (20). The Pγ C terminus binding residues, Gln752, Met758, Phe777, and Phe781 are shown in red. The metal ions Zn²⁺ and Mg²⁺ are shown in yellow and magenta, respectively. The C terminus of Pγ, Pγ(75–87), was generated and manually docked to the catalytic site using SYBYL (v.6.7) (Tripos Associates, St. Louis, MO). C, the clipped view is a 90° counterclockwise rotation around the vertical axis shown in B.
Essential Py binding residues, Gln\textsuperscript{752} and Met\textsuperscript{758}, of PDE6\textalpha{} have been identified via mutagenesis of Chi16 (6). A model of the PDE6\textalpha{} catalytic domain places Met\textsuperscript{758} at the opening of the catalytic pocket (6). Hypothetically, to ensure an effective catalytic block, the Py C terminus may lie over or might be inserted into the catalytic cavity. The former appears more likely because the catalytic pockets of different cyclic nucleotide PDEs are made up of highly conserved residues, whereas the inhibition by Py is a unique attribute of PDE6. We speculated that to cover the catalytic pocket, the Py C terminus, besides Met\textsuperscript{758}, interacts with additional nonconserved residues located at the perimeter of the entrance to the active site. The fact that the introduction of PDE6a\textalpha{}-(737–784) into PDE5/ PDE6a\textalpha{} chimera leads to a full inhibition of the PDE activity by Py suggests the PDE6a\textalpha{}-(737–784) segment contains most if not all residues interacting with the Py C terminus. In the PDE6a\textalpha{} model, PDE6a\textalpha{}-(737–784) comprises about half of the catalytic cavity mouth. Residues at three positions within PDE6a\textalpha{}-(737–784) (Lys\textsuperscript{760}, Phe\textsuperscript{777}, and Phe\textsuperscript{781}) are conserved among photoreceptor PDEs but have no homologous substitutions in PDE5. Supporting our hypothesis, replacement of two residues, Phe\textsuperscript{777} and Phe\textsuperscript{781}, by Ala in Chi16 has resulted in mutant PDEs that in comparison with Chi16 were less potently and incompletely inhibited by Py. Phe\textsuperscript{777} and Phe\textsuperscript{781} are located next to each other, opposite to the Met\textsuperscript{758} side of the catalytic opening (Fig. 3, B and C). Thus, it appears that the Py C terminus makes a bridge over the catalytic pocket. Such a model provides an interesting explanation to the results of an earlier study that examined inhibition of PDE6 by C-terminally truncated mutant PDEs (21). Truncations of one or two of the C-terminal Ile\textsuperscript{866}-Ile\textsuperscript{87} residues led to substantial increases in the $K_i$ value, whereas further truncations, up to 8–11 C-terminal residues, reduced the maximal inhibition of PDE6 activity without significantly affecting the $K_i$ value (21). A plausible interpretation is that Pyl\textsuperscript{866}-Ile\textsuperscript{87} interact with residues on one side of the catalytic pocket and other residues, perhaps Pyl\textsuperscript{77}–85, stretch over the catalytic cavity until Py reaches the opposite side. Accordingly, removal of Pyl\textsuperscript{866}-Ile\textsuperscript{87} decreases the affinity of Py for the PDE6 catalytic subunit, whereas progressive removal of Pyl\textsuperscript{77}–85 residues gradually facilitates access of cGMP to the catalytic site. To determine the orientation of the Py C terminus against the catalytic site and identify point-to-point interactions with PDE6a\textalpha{}, we examined the inhibition of Chi16 and the M758A, F777A, and F781A mutants of Chi16 by two Py mutants, Pyl\textsuperscript{866}A and Pyl\textsuperscript{87}A. The simplest prediction is that if a C-terminal Ile of Py interacts with one of the three PDE6a\textalpha{} residues, the corresponding mutant PDE would be inhibited comparably by Py and by the Py mutant. Complicating this prediction, side chains of Phe\textsuperscript{777} and Phe\textsuperscript{781} make a hydrophobic contact and thereby may support each other in the interaction with Py. The analysis of inhibition of Chi16 mutants by Py mutants indicates that Ile\textsuperscript{866} and Ile\textsuperscript{87} of Py interact with Phe\textsuperscript{777} and Phe\textsuperscript{781} of PDE6a\textalpha{}. Moderate increases in the $K_i$ values and reductions in the maximal inhibition of F777A and F781A caused by the Pyl\textsuperscript{866} substitution suggest that Ile\textsuperscript{866} probably contacts one or both of the PDE6a\textalpha{} residues. The failure of Pyl\textsuperscript{866}A to inhibit M758A is consistent with the notion that Ile\textsuperscript{866} binds Phe\textsuperscript{777}, but not Met\textsuperscript{758}. The lack of inhibition is likely caused by the inability of M758A and Py\textsuperscript{866}A to establish at least two of the three critical contacts involving Met\textsuperscript{758}, Phe\textsuperscript{777}, and Phe\textsuperscript{781}. The Py\textsuperscript{87}A mutant did not appreciably inhibit the activity of the M758A mutant PDE. Py\textsuperscript{87}A inhibited F777A stronger than F777A pointing to a probable contact between Pyl\textsuperscript{866} and Phe\textsuperscript{781} of PDE6a\textalpha{}. The incomplete inhibition of mutant PDEs by Py or Py mutants most likely reflects equivalent partial inhibition of both active sites of the catalytic dimer, rather than the loss of inhibition at one site.

The analysis of Py secondary structure predicts an $\alpha$-helical structure for the C-terminal residues Py\textsuperscript{77}–85 (30). The C terminus of Py, Py\textsuperscript{77}–87, manually docked to the PDE6a\textalpha{} catalytic site is shown in Fig. 3, B and C. The model assumes the helical structure of Py\textsuperscript{77}–84 and the contacts between Py\textsuperscript{866}–Ile\textsuperscript{87} and PDE6a\textalpha{} Phe\textsuperscript{777}–Phe\textsuperscript{781}. This orientation of Py is also consistent with Glu\textsuperscript{752} of PDE6a\textalpha{} (6) making a contact with a Py residue located N-terminally to Py\textsuperscript{77}–87.

The remarkable ability of photoreceptor PDEs to hydrolyze cGMP with a catalytic rate constant of $\approx 4000–5500$ moles of cGMP per mole of PDE6 (12–15) is essential to the signal amplification in the visual cascade. All catalytic subunits of cyclic nucleotide PDEs contain two strictly conserved metal binding motifs, His-Asn-X-X-His (motif I) and His-Asp-X-X-His (motif II). In PDE6a\textalpha{} these motifs are as follows: His\textsuperscript{561}-Asn\textsuperscript{562}-Trp\textsuperscript{563}-Arg-His\textsuperscript{564} and His\textsuperscript{597}-Asp\textsuperscript{598}. A model of cAMP docked in the PDE4 active site demonstrates that ME1 and ME2 bind the cyclic phosphate, position a potential water molecule for the nucleophilic attack, and would serve to stabilize the transition state (20). In view of the role of metal binding sites in hydrolysis of cyclic nucleotides, we have considered the motifs I and II as probable structural determinants of the catalytic properties of PDE6. Motifs I and II are practically identical in PDE5 and PDE6. Therefore, a spatial orientation of these sites might be a potential key factor for cGMP hydrolysis. Motif I comprises the N-terminal portion of the helix-\textalpha{}, and motif II is in the loop connecting helices 7 and 8. A PDE5/ PDE6a\textalpha{} chimera, Chi20, was generated by replacing a PDE6a\textalpha{} domain containing helices \textalpha{}-a-a into PDE5. The analysis of Chi20 revealed a more than 10-fold increase in the maximal catalytic rate accompanied by a 5-fold increase in the $K_m$ value. Subsequent chimeric PDE, Chi21, containing only helix \textalpha{} of PDE6a\textalpha{} displayed catalytic properties similar to those of Chi20. An alignment of sequences of photoreceptor PDEs and PDE5 corresponding to the helix-\textalpha{} shows a high degree of homology with the notable exception of residues at two positions corresponding to PDE6a\textalpha{} Gly\textsuperscript{562} and Gly\textsuperscript{566}. Gly\textsuperscript{562} of PDE6a\textalpha{} is conserved only in the PDE6 family, but substituted by Ala in PDE5 (Fig. 3A). Importantly, Gly\textsuperscript{562} immediately follows His\textsuperscript{561} from motif I. His\textsuperscript{561}, by analogy to PDE4, is involved in coordination of ME1, and in the positioning of His\textsuperscript{557} to accomplish the protonation of the O3' leaving group (20). To probe the role of the Gly residues, a doubly substituted PDE5 mutant, A608G/A612G, has been made. The $k_{cat}$ value of the A608G/A612G mutant was comparable with those of Chi20 and Chi21, and 10-fold higher than that of PDE5. These results suggest that the Gly residues are in part responsible for the catalytic characteristics of PDE6. Most likely, they allow for a positioning of motif I that is most favorable for cGMP hydrolysis. Other yet to be defined determinants contribute to the unique catalytic power of PDE6, because the achieved $k_{cat}$ value is still $\approx 40–50$-fold lower than $k_{cat}$ described for native activated PDE6. Overall, our results suggest that a progressive incorporation of PDE6 domains or residues into PDE5 not only allows a structure-function analysis of PDE6, but also repre-
sents a realistic approach to generate a chimeric enzyme that would be functionally indistinguishable from PDE6.

Acknowledgment—We thank Boyd Knosp for assistance with molecular modeling.

REFERENCES
1. Chabre, M., and Deterre, P. (1989) Eur. J. Biochem. 179, 255–266
2. Yarfitz, S., and Hurley, J. B. (1994) J. Biol. Chem. 269, 14329–14332
3. Piriev, N. I., Yamashita, C., Samuel, G., and Farber, D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9340–9344
4. Qin, N., and Baehr, W. (1994) J. Biol. Chem. 269, 14329–14332
5. Piriev, N. I., Yamashita, C., Samuel, G., and Farber, D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9340–9344
6. Qin, N., and Baehr, W. (1994) J. Biol. Chem. 269, 3265–3271
7. Granovsky, A. E., Natochin, M., McEntaffer, R. L., Haik, T. L., Francis, S. H., Corbin, J. D. and Artemyev, N. O. (1998) J. Biol. Chem. 273, 24485–24490
8. Granovsky, A. E., and Artemyev, N. O. (2000) J. Biol. Chem. 275, 41258–41262
9. McAllister-Lucas, L. M., Sonnenburg, W. K., Kadlec, A., Seger, D., Trong, H. L., Colbran, J. L., Thomas M. K., Walsh, K. A., Francis, S. H., Corbin, J. D. and Beavo, J. A. (1998) J. Biol. Chem. 273, 22863–22873
10. Gillespie, P. G., and Beavo, J. A. (1989) Mol. Pharmacol. 36, 773–781
11. Thomas, M. K., Francis, S. H., and Corbin, J. D. (1990) J. Biol. Chem. 265, 14961–14970
12. Turko, I. V., Ballard, S. A., Francis, S. H., and Corbin, J. D. (1999) Mol. Pharmacol. 56, 124–130
13. Thomas, M. K., Francis, S. H., and Corbin, J. D. (1990) J. Biol. Chem. 265, 14961–14970
14. Turko, I. V., Ballard, S. A., Francis, S. H., and Corbin, J. D. (1999) Mol. Pharmacol. 56, 124–130
15. Thompson, W. J., and Appleman, M. M. (1971) Biochemistry 10, 311–316
16. Natochin, M., and Artemyev, N. O. (2000) Methods Enzymol. 315, 539–554
17. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254
18. Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 4350–4354
19. Guex, N., and Peitsch, M. C. (1997) Electrophoresis 18, 4673–4680
20. Skiba, N. P., Artemyev, N. O., and Hamm, H. E. (1995) J. Biol. Chem. 270, 13210–13215
21. Skiba, N. P., Artemyev, N. O., and Hamm, H. E. (1995) J. Biol. Chem. 270, 13210–13215
22. Thomas, M. K., Francis, S. H., and Corbin, J. D. (1990) J. Biol. Chem. 265, 14961–14970
23. McAllister-Lucas, L. M., Sonnenburg, W. K., Kadlec, A., Seger, D., Trong, H. L., Colbran, J. L., Thomas M. K., Walsh, K. A., Francis, S. H., Corbin, J. D. and Beavo, J. A. (1998) J. Biol. Chem. 273, 22863–22873
24. Gillespie, P. G., and Beavo, J. A. (1989) Mol. Pharmacol. 36, 773–781
25. McAllister-Lucas, L. M., Sonnenburg, W. K., Kadlec, A., Seger, D., Trong, H. L., Colbran, J. L., Thomas M. K., Walsh, K. A., Francis, S. H., Corbin, J. D. and Beavo, J. A. (1998) J. Biol. Chem. 273, 22863–22873
26. Thomas, M. K., Francis, S. H., and Corbin, J. D. (1990) J. Biol. Chem. 265, 14961–14970
27. Turko, I. V. (1998) J. Biol. Chem. 273, 6460–6466
28. Moa, H., Grazio, H. J., III, Cook, T. A., Beavo, J. A., and Cote, R. H. (1999) J. Biol. Chem. 274, 18813–18820
29. Leskov, I. B., Klenchin, V. A., Handy, J. W., Whitlock, G. G., Govardovskii, V. I., Bovas, M. D., Lamb, T. D., Pugh, E. N., and Arshavy, V. Y. (2000) Neuron 27, 525–537
30. Gillespie, P. G., and Beavo, J. A. (1988) J. Biol. Chem. 263, 8131–8141
31. Dumke, C. L., Arshavy, V. Y., Calvert, P. D., Bownds, M. D., and Pugh, E. N., Jr. (1994) J. Gen. Physiol. 103, 1071–1098
32. Turko, I. V., Haik, T. L., McAllister-Lucas, L. M., Burns, F., Francis, S. H., and Corbin, J. D. (1996) J. Biol. Chem. 271, 22240–22244
